| Report | Options implied | Actual move | Market was |
|---|---|---|---|
| May 6, 2026 | ±2.2% | -2.5% | under-priced |
| November 5, 2025 | ±2.3% | +1.9% | over-priced |
| August 7, 2025 | ±1.5% | -0.2% | over-priced |
| May 8, 2025 | ±1.7% | +7.0% | under-priced |
| November 7, 2024 | ±2.3% | -5.0% | under-priced |
| August 1, 2024 | ±2.2% | -5.5% | under-priced |
| May 2, 2024 | ±1.8% | +5.7% | under-priced |
| November 9, 2023 | ±2.2% | -8.4% | under-priced |
| Quarter | EPS (dil.) | Revenue | Net income |
|---|---|---|---|
| Q1 FY2026 | $1.07 | $4.9B | $723M |
| Q4 FY2025 | $-0.81 | $3.9B | $-549M |
| Q3 FY2025 | $-0.47 | $2.6B | $-318M |
| Q2 FY2025 | $1.92 | $6.5B | $1.3B |
Corteva, Inc. Common Stock (CTVA) reports in 98 days, with the next report estimated for September 19, 2026. Across the last 8 reports, options priced an average ±2.0% earnings move while the stock actually moved 4.5% on average — the market has tended to under-price CTVA's earnings risk. Fundamentals into the print: EPS up 12.6% year-over-year, revenue up 11.0%. QuantLogix's live 5-factor engine currently reads CTVA as a buy at 57/100.
Implied move is derived from at-the-money option pricing; actual moves are close-to-close on report days. Next-report dates are estimates until confirmed by the company. Educational market analysis, not investment advice. Browse all signal scorecards →